Ignite Creation Date:
2024-05-06 @ 12:22 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01568580
Status:
COMPLETED
Last Update Posted:
2012-04-02
First Post:
2012-03-22
Brief Title:
Efficacy and Safety of Recombinant Factor VIII GreenGene in Patients With Hemophilia A
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
Open-label Non-comparative Multicenter Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII GreenGene in Previously Treated Patients With Hemophilia A
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study the evaluation of efficacy and safety of GreenGene Recombinant Factor VIII
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None